Reproductive Aging — MCQs

10 questions

A 46-year-old woman presents for her annual examination. Her main complaint is frequent sweating episodes with a sensation of intense heat starting at her upper chest and spreading up to her head. These have been intermittent for the past 6 to 9 months but are gradually worsening. She has three to four flushing/sweating episodes during the day and two to three at night. She occasionally feels her heart race for about a second, but when she checks her pulse it is normal. She reports feeling more tired and has difficulty with sleep due to sweating. She denies major life stressors. She also denies weight loss, weight gain, or change in bowel habit. Her last menstrual cycle was 3 months ago. Physical examination is normal. Which treatment is most appropriate in alleviating this woman's symptoms?

A 35-year-old woman presents with 4 months of amenorrhea, increased FSH, LH, and decreased estrogen. What is the most likely diagnosis?

A child with decreased levels of LH, FSH and Testosterone presents with delayed puberty. Which of the following is the most likely Diagnosis

35 yr old with 4 months amenorrhea with increased FSH, decreased estrogen. What is the diagnosis?

Which of the following statements about the postmenopausal state is false?

Which of the following hormones will be affected most after the change in sex hormone binding globulin?

Pseudotumor cerebri is seen in -

Which one of the following is defined as "the average number of children a woman would have if she were to pass through her reproductive years, bearing children at the same rates as the women now in each age group" ?

Which of the following is correct about the feedback hormone marked as $X$ ?

Q10

At the time point indicated by the arrow, the hormone levels are:

Reproductive Aging Indian Medical PG Practice Questions and MCQs

Question 1: A 46-year-old woman presents for her annual examination. Her main complaint is frequent sweating episodes with a sensation of intense heat starting at her upper chest and spreading up to her head. These have been intermittent for the past 6 to 9 months but are gradually worsening. She has three to four flushing/sweating episodes during the day and two to three at night. She occasionally feels her heart race for about a second, but when she checks her pulse it is normal. She reports feeling more tired and has difficulty with sleep due to sweating. She denies major life stressors. She also denies weight loss, weight gain, or change in bowel habit. Her last menstrual cycle was 3 months ago. Physical examination is normal. Which treatment is most appropriate in alleviating this woman's symptoms?

A. Estrogen plus progesterone (Correct Answer)
B. Citalopram
C. Estrogen
D. Levothyroxine

Explanation: ***Estrogen plus progesterone*** - This patient's symptoms (hot flashes, night sweats, fatigue, sleep disturbance, irregular menses) are highly suggestive of **perimenopause/menopause**. **Hormone replacement therapy (HRT)** with estrogen and progesterone is the most effective treatment for managing severe menopausal symptoms. - Adding **progesterone** is crucial for women with an intact uterus to prevent **endometrial hyperplasia** and **endometrial cancer** caused by unopposed estrogen therapy. *Citalopram* - **Selective serotonin reuptake inhibitors (SSRIs)** like citalopram can reduce the frequency and severity of hot flashes, but they are generally reserved for women who cannot take or prefer not to take HRT due to contraindications or concerns. - SSRIs are less effective than HRT for severe vasomotor symptoms and do not address other menopausal symptoms like vaginal dryness or bone loss. *Estrogen* - While estrogen is the primary hormone for alleviating menopausal symptoms, administering **unopposed estrogen** to a woman with an intact uterus significantly increases the risk of **endometrial hyperplasia** and **endometrial carcinoma**. - Progesterone is necessary to counteract the proliferative effects of estrogen on the endometrium, preventing these risks. *Levothyroxine* - **Levothyroxine** is used to treat **hypothyroidism**, a condition that can cause fatigue, weight changes, and menstrual irregularities. - However, the patient's primary symptoms of prominent hot flashes and night sweats are not characteristic of hypothyroidism, and her physical examination is normal, making this diagnosis less likely.

Question 2: A 35-year-old woman presents with 4 months of amenorrhea, increased FSH, LH, and decreased estrogen. What is the most likely diagnosis?

A. Premature ovarian insufficiency (Correct Answer)
B. Menopause
C. Late menopause
D. Perimenopause

Explanation: ***Premature ovarian insufficiency (POI)*** - The patient's age (35 years) combined with 4 months of **amenorrhea**, increased **FSH** and **LH**, and decreased **estrogen** is characteristic of premature ovarian insufficiency (also called premature ovarian failure). - The hormonal profile (**hypergonadotropic hypogonadism**) indicates ovarian failure occurring before the age of **40 years**, which defines POI. - POI affects approximately **1% of women under 40** and can present with amenorrhea, infertility, and symptoms of estrogen deficiency. *Menopause* - Menopause is diagnosed after **12 consecutive months of amenorrhea** in a woman, typically occurring around age **51 years** (natural menopause). - While the hormonal profile of elevated FSH/LH and low estrogen is consistent with menopause, the patient's **age of 35 years** and **only 4 months of amenorrhea** do not meet the criteria for natural menopause. *Late menopause* - Late menopause refers to menopause occurring at a later age than average, typically after age **55 years**. - This diagnosis is completely inconsistent with the patient's age of 35 years. *Perimenopause* - Perimenopause is the transitional phase leading up to menopause, characterized by **irregular menstrual cycles** and **fluctuating hormone levels**. - While FSH levels may be elevated at times, perimenopause typically shows **variable hormone levels** rather than the sustained pattern of high FSH/LH with low estrogen seen in this case. - The **sustained amenorrhea** and pronounced hormonal shifts indicate ovarian failure (POI) rather than perimenopausal transition.

Question 3: A child with decreased levels of LH, FSH and Testosterone presents with delayed puberty. Which of the following is the most likely Diagnosis

A. Klinefelter's syndrome
B. Kallman's syndrome (Correct Answer)
C. Testicular infection
D. Androgen Insensitivity Syndrome

Explanation: ***Kallman's syndrome*** - **Kallmann's syndrome** is characterized by **isolated hypogonadotropic hypogonadism**, meaning the hypothalamus fails to produce **GnRH**, leading to low LH and FSH, and consequently low testosterone, causing delayed puberty. - A key distinguishing feature is the association with **anosmia or hyposmia** (impaired sense of smell) due to abnormal migration of olfactory neurons and GnRH-producing neurons. *Klinefelter's syndrome* - This condition is characterized by **primary hypogonadism** (testicular failure) due to an extra X chromosome (47,XXY), leading to **high LH and FSH** in an attempt to stimulate the failing testes. - Although testosterone is low and puberty is delayed, the **elevated gonadotropins** differentiate it from Kallmann's syndrome. *Testicular infection* - An infection like **orchitis** can lead to testicular damage and *primary hypogonadism*, resulting in low testosterone. - However, similar to Klinefelter's, this would typically cause **elevated LH and FSH** due to the lack of negative feedback from the testes. *Androgen Insensitive syndrome* - In **Androgen Insensitivity Syndrome (AIS)**, testosterone levels are typically **normal or even elevated**, but the body's cells are unable to respond to androgens due to defective receptors. - This condition presents with a female phenotype despite a 46,XY karyotype, and **gonadotropin levels (LH and FSH) are usually normal to high**, not decreased.

Question 4: 35 yr old with 4 months amenorrhea with increased FSH, decreased estrogen. What is the diagnosis?

A. Premature ovarian failure (Correct Answer)
B. Pituitary dysfunction
C. Hypothalamic dysfunction
D. Polycystic Ovary Syndrome

Explanation: ***Premature ovarian failure*** - The combination of **amenorrhea** for 4 months in a 35-year-old, with **increased FSH** and **decreased estrogen**, is characteristic of premature ovarian failure, indicating the ovaries are no longer responding to FSH stimulation. - This condition signifies the cessation of ovarian function before the age of 40, leading to menopausal symptoms and infertility. *Pituitary dysfunction* - Pituitary dysfunction might lead to **decreased FSH** (hypogonadotropic hypogonadism) due to insufficient stimulation of the ovaries, not increased FSH. - In cases of pituitary adenomas, increased prolactin can cause amenorrhea, but FSH would not be elevated in the manner described. *Hypothalamic dysfunction* - Hypothalamic dysfunction, such as **functional hypothalamic amenorrhea**, typically presents with **low or normal FSH and LH levels** (hypogonadotropic hypogonadism) due to reduced GnRH pulsatility. - This condition is often associated with stress, excessive exercise, or low body weight, and would not cause elevated FSH as seen here. *Polycystic Ovary Syndrome* - **Polycystic Ovary Syndrome (PCOS)** is characterized by **anovulation**, resulting in amenorrhea or oligomenorrhea, but typically involves **elevated androgens** and a **high LH-to-FSH ratio**, with FSH levels generally normal or low, and estrogen levels often normal or slightly elevated. - It would not present with simultaneously high FSH and low estrogen, which points to ovarian failure rather than anovulation with intact ovarian reserve.

Question 5: Which of the following statements about the postmenopausal state is false?

A. High FSH
B. Low LH (Correct Answer)
C. Low estrogen
D. High androgen

Explanation: ***Low LH*** - This statement is **FALSE** because **LH (luteinizing hormone) levels are markedly elevated** in postmenopausal women. - The drop in ovarian estrogen production removes the **negative feedback** on the pituitary, leading to **increased LH and FSH secretion**. - Both gonadotropins (LH and FSH) are characteristically **high in postmenopause**. *High FSH* - This statement is true; **FSH (follicle-stimulating hormone) levels are markedly elevated** in postmenopausal women. - The elevated FSH is a direct consequence of the **lack of negative feedback** from inhibin and estrogen produced by the ovaries. *Low estrogen* - This statement is true; **estrogen levels plummet significantly** after menopause due to the **cessation of ovarian follicular activity**. - This **estrogen deficiency** is responsible for many postmenopausal symptoms, such as hot flashes, vaginal atrophy, and bone loss. *High androgen* - While androgens are still produced by the adrenal glands and ovaries postmenopause, their **absolute levels also decline with age**. - The statement is somewhat ambiguous, but androgens do **not increase** in absolute terms; rather, the **estrogen-to-androgen ratio changes** because estrogen falls more dramatically.

Question 6: Which of the following hormones will be affected most after the change in sex hormone binding globulin?

A. Testosterone (Correct Answer)
B. Progesterone
C. DHEA
D. Estrogen

Explanation: ***Testosterone*** - **Sex hormone-binding globulin (SHBG)** binds primarily to **testosterone** (and dihydrotestosterone) with **high affinity**. - SHBG has approximately **5 times greater affinity** for testosterone compared to estradiol. - A change in SHBG levels will significantly impact the proportion of **free (biologically active) testosterone** available in the circulation, thus affecting its overall function and measurement. - This makes testosterone the hormone **most affected** by changes in SHBG levels. *Progesterone* - **Progesterone** is primarily bound to **albumin** and **corticosteroid-binding globulin (CBG)**, not SHBG. - Therefore, changes in SHBG would have minimal direct impact on progesterone levels or its bioavailability. *DHEA* - **Dehydroepiandrosterone (DHEA)** is mostly bound to **albumin** in the blood. - Its binding to SHBG is negligible, making changes in SHBG irrelevant to its overall circulating levels or activity. *Estrogen* - **Estrogen (estradiol)** also binds to SHBG, but with **significantly lower affinity** than testosterone (approximately 5-fold less). - While affected by SHBG changes, the impact is less pronounced than on testosterone due to the lower binding affinity and its additional binding to albumin.

Question 7: Pseudotumor cerebri is seen in -

A. Obese women in the age group 20-40 yrs. (Correct Answer)
B. Obese males 20-40 yrs.
C. Thin males 50-60 yrs.
D. Thin females 50-60 yrs.

Explanation: ***Obese women in the age group 20-40 yrs.*** - **Pseudotumor cerebri** (also known as idiopathic intracranial hypertension) is most commonly seen in **obese women** of childbearing age, typically between **20 and 40 years old** [1]. - Risk factors include **obesity** and certain medications like **tetracyclines**, **excess vitamin A**, or **oral contraceptives** [1]. *Obese males 20-40 yrs.* - While obesity is a risk factor, **males** are significantly less commonly affected by pseudotumor cerebri than females [1]. - The disease has a strong predilection for the female gender in this age group. *Thin males 50-60 yrs.* - **Pseudotumor cerebri** is rarely observed in individuals who are **thin** and in older age groups like **50-60 years old**. - This demographic does not align with the typical patient profile for this condition. *Thin females 50-60 yrs.* - Similar to thin males, **thin females** in the **50-60 year age group** are not typically affected by pseudotumor cerebri. - The condition primarily impacts young to middle-aged obese women.

Question 8: Which one of the following is defined as "the average number of children a woman would have if she were to pass through her reproductive years, bearing children at the same rates as the women now in each age group" ?

A. Net Reproduction Rate (NRR)
B. Total Fertility Rate (TFR) (Correct Answer)
C. General Fertility Rate (GFR)
D. Age-Specific Fertility Rate (ASFR)

Explanation: **Total Fertility Rate (TFR)** - The **Total Fertility Rate (TFR)** is a measure of the average number of children a woman is expected to have over her lifetime, assuming current age-specific fertility rates. - It is a synthetic measure that reflects the reproductive patterns of a given population at a specific time. *Net Reproduction Rate (NRR)* - The **Net Reproduction Rate (NRR)** is similar to the Gross Reproduction Rate but also accounts for **mortality rates** among females before completing their reproductive years. - It measures the number of daughters a newborn girl can expect to have during her lifetime, considering current age-specific fertility and mortality rates. *General Fertility Rate (GFR)* - The **General Fertility Rate (GFR)** calculates the number of live births per 1,000 women of reproductive age (typically 15-49 years). - It is a broader measure than age-specific rates but does not project the total number of children a woman might have. *Age-Specific Fertility Rate (ASFR)* - An **Age-Specific Fertility Rate (ASFR)** measures the number of live births to women in a particular age group per 1,000 women in that same age group. - While it provides data for specific age cohorts, it does not combine these to give a lifetime average as described in the definition.

Question 9: Which of the following is correct about the feedback hormone marked as $X$ ?

A. Inhibin A
B. Inhibin B (Correct Answer)
C. Progesterone
D. Estrone

Explanation: **Correct: Inhibin B** - The diagram shows a feedback loop where "X" is produced downstream and inhibits the anterior pituitary. This fits the role of **Inhibin B**, which is primarily secreted by the **granulosa cells** of the ovary and **Sertoli cells** of the testis. - **Inhibin B** selectively inhibits the secretion of **FSH** from the anterior pituitary, as indicated by the negative feedback arrow pointing towards the pituitary. - Inhibin B is the key hormone in the follicular phase that provides selective FSH feedback control. *Incorrect: Inhibin A* - **Inhibin A** is predominantly secreted by the **corpus luteum** during the luteal phase of the menstrual cycle and is involved in placental function during pregnancy. - Its levels peak later in the cycle compared to Inhibin B during the follicular phase, and its primary role is not the selective inhibition of FSH shown in this diagram's context for follicular development. *Incorrect: Progesterone* - **Progesterone** is a steroid hormone primarily involved in preparing the uterus for pregnancy and maintaining it during early pregnancy. - While it exerts negative feedback on GnRH and LH/FSH, it is typically secreted by the corpus luteum after ovulation, and the diagram appears to depict a more general inhibitory feedback on FSH. *Incorrect: Estrone* - **Estrone** is one of the three major naturally occurring estrogens but is less potent than estradiol. - While estrogens provide feedback on the hypothalamus and pituitary, the diagram specifically labels "Estrogen" separately, and "X" represents a distinct feedback hormone, making estrone an unlikely specific fit for "X."

Question 10: At the time point indicated by the arrow, the hormone levels are:

A. Decreased estrogen, increased progesterone
B. Increased estrogen, increased progesterone
C. Decreased estrogen, decreased progesterone
D. Increased estrogen, decreased progesterone (Correct Answer)

Explanation: ***Increased estrogen, decreased progesterone*** - The arrow (red circle) points to Day 14, marking the approximate time of **ovulation**. At this point, the graph shows that **estrogen levels peak** just before ovulation and begin to decrease during ovulation. - Progesterone levels are relatively **low** during the follicular phase and only start to significantly increase **after ovulation** as the corpus luteum forms. *Decreased estrogen, increased progesterone* - This hormonal profile is characteristic of the **mid to late luteal phase**, not ovulation. - During the luteal phase, post-ovulation, the **corpus luteum** predominantly produces **progesterone**, leading to its increase, while estrogen levels decline from their pre-ovulatory peak. *Increased estrogen, increased progesterone* - While estrogen is high just before ovulation, **progesterone remains low** until after ovulation. - An increase in both significant progesterone and estrogen would be more indicative of the middle of the **luteal phase** when the corpus luteum is fully functional and producing both hormones in higher amounts. *Decreased estrogen, decreased progesterone* - This hormone profile typically occurs at the **very end of the luteal phase** if pregnancy does not occur, leading to the breakdown of the corpus luteum and subsequent menstruation. - It also characterizes the early follicular phase, not the time around ovulation.

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free